Logo image link to Home Page

http://www.yaupontherapeutics.com/images/spacer_5x5.gif

Home

Overview

Directors/Investors

Products

Press

Management

Image

Management

The management team is a collection of experienced pharmaceutical executives, proven entrepreneurs, and world class scientists. Having worked together in the past, they have recently come together to build Yaupon Therapeutics into a successful enterprise.

Robert Alonso, President & CEO is a seasoned executive with 15 years of domestic and international pharmaceutical experience in licensing, drug development and marketing. He has held management positions for large multi-nationals such as Merck and Hofmann La Roche as well as biotech start-ups with Layton Bioscience. Mr. Alonso has run a $200 million infectious disease franchise and he has closed over 15 licensing deals. Mr. Alonso has an MBA from F.W. Olin Graduate School at Babson College.

Peter Crooks, Ph.D., Chief Scientific Officer, is an internationally recognized expert in medicinal chemistry with extensive experience in drug discovery and development. He is full professor and an Endowed Chair in the Division of Pharmaceutical Sciences, University of Kentucky and works part-time with Yaupon. Dr. Crooks has authored over 500 papers and holds more than 70 patents in the area of drug discovery. He is the recipient of numerous awards. Dr. Crooks received his B.S., M.S., and Ph.D. degrees from the University of Manchester, U.K.

Thomas P. Hess, CPA, Senior Vice President, Finance, and Chief Financial Officer, is a seasoned financial executive with 20 years of domestic and international experience. Prior to joining Yaupon Therapeutics, Mr. Hess was the Vice President, Finance and Chief Financial Officer of Adolor Corporation from 2005 to 2008 where his responsibilities included investor relations, SEC reporting and cash management. From 2003 until joining Adolor Corporation, Mr. Hess was Corporate Controller of Vicuron Pharmaceuticals, Inc, a biopharmaceutical company that was acquired by Pfizer I nc. in 2005 for $1.9 billion. From 2000 until 2003, Mr. Hess was Controller of Innovative Solutions and Support, Inc., a manufacturer of high tech avionics equipment. Prior to joining Innovative Solutions and Support, Inc., Mr. Hess was with KPMG LLP for ten years in various positions, including as a senior manager. Mr. Hess has a Bachelor of Science in accounting from Pennsylvania State University and a Masters of Business Administration in Finance from the University of Pittsburgh.

Martin Stogniew, Ph.D., Chief Technology Officer, brings 28 years of senior executive experience in the pharmaceutical industry.  He has been responsible for all areas of domestic and international drug development, including proprietary, generic, over the counter drugs, and nutritional supplements.  Mr. Stogniew has made significant contributions to eight New Drug Application approvals by the FDA, twenty-six US patents issued, and three major M&A deals.  Most recently he was Executive Vice President, Chief Technology Officer of Prestwick Pharmaceuticals and was accountable for all technical and regulatory diligence during the sale of the company to Biovail for $150 M.  Previously he was Executive Vice President, Scientific Affairs and Executive Officer for Vicuron Pharmaceuticals where he played an integral part in the sale to Pfizer for $1.9 B.  Prior to Vicuron he was Vice President, Pharmaceutical Sciences and Corporate Officer for US Bioscience, which he helped sell for $492 M.  Mr. Stogniew completed a post doctoral fellowship at The Johns Hopkins University, School of Medicine, earned a Ph.D. in Medicinal Chemistry from the University of Maryland and received a B.S. in Pharmacy with honors from the University of Maryland.  


Philip S. Schein, MD, DSc, FRCP, is widely regarded as a leading international authority in the treatment of cancer. Currently he a Visiting Professor in Cancer Pharmacology, University of Oxford and as President of The Schein Group, which provides consultative services to the pharmaceutical industry. Dr. Schein served as a Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch, National Cancer Institute. His next appointment was at the Georgetown University School of Medicine in Washington, DC, as Professor of Medicine and Pharmacology, Chief of Medical Oncology and Scientific Director of the Vincent T. Lombardi Cancer Research Center. Subsequently he served as Vice President of Worldwide Clinical Research and Development, and Director of the Laboratory of Molecular Oncology, SmithKline & French Laboratories, where he had responsibility for all SK&F clinical research and development activities.  In 1987 Dr. Schein founded U.S. Bioscience, a publically-traded pharmaceutical company focused on cancer and AIDS, and while serving as Chairman and CEO he took three products, Ethyol, Hexalen and Neutrexin, through development and regulatory approval in the US, Europe, Canada and other countries. Dr. Schein has held major positions in the field of Medical Oncology. He has served as President of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. He has also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research. In 1984, in a survey of department chairmen and clinical-program chiefs at 87 medical schools, Dr. Schein was ranked as one of the 120 best doctors in America, and one of four listed in Oncology.  He has authored over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents.  He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education. Dr. Schein is a Fellow of the Royal College of Physicians of London and the Royal College of Physicians and Surgeons at Glasgow. While serving as CEO of U.S. Bioscience he was the 1992 recipient of the Delaware Valley's Entrepreneur of the Year Award in the "Emerging Company" category, and in 1995 the region’s 3rd Annual Enterprise Awards designated U.S. Bioscience the “Technology Transfer Company of the Year.”  He has been awarded a Honorary Doctor of Science degree from Rutgers University and a Doctorate Honoris Causa from the National University of Rosario, Argentina.  He serves on the Board of Directors of Medicis, and on the scientific advisory boards of several companies in the biotechnology/pharmaceutical industry. 


Office Address:

Radnor, PA

259 North Radnor-Chester Road, Suite 205
Radnor, PA 19087
P 610-975-9290
F 610-975-9012

For additional information about Yaupon Therapeutics, please email us at info@yaupontherapeutics.com

http://www.yaupontherapeutics.com/images/spacer_5hx100h.gif

Translating University Research into Medicineh

http://www.yaupontherapeutics.com/images/spacer_5wx50h.gif

http://www.yaupontherapeutics.com/images/spacer1x1.gif

http://www.yaupontherapeutics.com/images/spacer1x1.gif

Home • Overview • Directors/Investors • Products • Press • Management